ArticleMolecular neurodegeneration2024
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology.
Open access · goldAbstract read
In one paragraph
Article in Molecular neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Quantification of Phosphorylated Tau Protein in Alzheimer's Disease Patients' Fluids With Electrolyte-Gated Organic Transistor Biosensors.Advanced healthcare materials · 2026Article
- Tau in Alzheimer's disease: Shaping the future patient journey.The journal of prevention of Alzheimer's disease · 2026Review
- Computational Approaches to Neurological Disorder Diagnosis: An In-Depth Review of Current Methods and Future ProspectsCurrent medical imaging · 2026Review
- Olink Proteomics in Heart Failure: A Comprehensive Review of Applications From Biomarker Discovery to Pathophysiological Insights and Clinical Implementation.Reviews in cardiovascular medicine · 2026Review
- APOE ɛ4 carriership determines a faster plasma p-tau217 progression in Aβ-positive individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Oral Microbiome-Derived Proteins in Brain Extracellular Vesicles Circulate and Tie to Specific Dysbiotic and Neuropathological Profiles in Age-Related Dementias.Molecular & cellular proteomics : MCP · 2025Article
- Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer's disease in a multicenter and multiethnic aging population.Nature aging · 2025Article
- Phosphorylation-Induced Self-Coacervation versus RNA-Assisted Complex Coacervation of Tau Proteins.Journal of the American Chemical Society · 2025Article
- A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.Brain : a journal of neurology · 2025Article
- Identify biological Alzheimer's disease using a novel nucleic acid-linked protein immunoassay.Brain communications · 2025Article
- Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay.Alzheimer's research & therapy · 2024Article
- P-tau217 as a Reliable Blood-Based Marker of Alzheimer's Disease.Biomedicines · 2024Review
- A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests.medRxiv : the preprint server for health sciences · 2024Article
- Benchmarking of a multi-biomarker low-volume panel for Alzheimer's Disease and related dementia research.medRxiv : the preprint server for health sciences · 2024Article
- Biomarker-based staging of Alzheimer disease: rationale and clinical applications.Nature reviews. Neurology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 9 institutions in 5 countries.
Joseph Therriault *Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada.ORCID 0000-0002-7826-4781
Marcel S Woo *Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada.
Gemma Salvadó *Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.
Johan GobomDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, S-431 80, Sweden.
Thomas K KarikariDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, S-431 80, Sweden.
Shorena JanelidzeDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.
Stijn ServaesTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada.
Nesrine RahmouniTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada.
Cécile TissotTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, S-431 80, Sweden.
Andréa Lessa BenedetDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.
Laia Montoliu-GayaDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, S-431 80, Sweden.
Arthur C MacedoTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada.
Firoza Z LussierTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada.
Jenna StevensonTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada.
Paolo VitaliDepartment of Neurology and Neurosurgery, McGill University, Montreal, QC, H3A 2B4, Canada.
Manuel A FrieseDepartment of Neurology, Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany.
Gassan MassarwehDepartment of Neurology and Neurosurgery, McGill University, Montreal, QC, H3A 2B4, Canada.
Jean-Paul SoucyDepartment of Neurology and Neurosurgery, McGill University, Montreal, QC, H3A 2B4, Canada.
Tharick A PascoalDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, 15213, USA.
Erik StomrudDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.
Sebastian PalmqvistDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.
Niklas Mattsson-CarlgrenDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.
Serge GauthierTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, S-431 80, Sweden.
Oskar HanssonDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, S-431 80, Sweden.
Pedro Rosa-NetoTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé Et de Services Sociaux (CIUSSS) de l'Ouest-de-L'Île-de-Montréal, 6875 La Salle Blvd - FBC Room 3149, Montréal, Québec, H4H 1R3, Canada. pedro.rosa@mcgill.ca.
Douglas Mental Health University Institute · CALund University · SEMcGill University · CAUniversity of Pittsburgh · USSahlgrenska University Hospital · SEUniversität Hamburg · DEKing's College London · GBUniversity of Gothenburg · SEUniversity of Wisconsin–Madison · US
Funding
Plasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in bloodR01AG083874 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas K Karikari · 2023 to 2026
$14.5MNIA NIH HHS R01 AG083874
Abstract
backgroundAntibody-based immunoassays have enabled quantification of very low concentrations of phosphorylated tau (p-tau) protein forms in cerebrospinal fluid (CSF), aiding in the diagnosis of AD. Mass spectrometry enables absolute quantification of multiple p-tau variants within a single run. The goal of this study was to compare the performance of mass spectrometry assessments of p-tau
methodsWe measured p-tau
resultsMass spectrometry and immunoassays of p-tau
conclusionsOur results suggest that while similar overall, immunoassay-based p-tau biomarkers are slightly superior to antibody-free mass spectrometry-based p-tau biomarkers. Future work is needed to determine whether the potential to evaluate multiple biomarkers within a single run offsets the slightly lower performance of antibody-free mass spectrometry-based p-tau quantification.
Indexed as
Alzheimer DiseaseAmyloidogenic ProteinsBiomarkersHumansImmunoassayMass SpectrometryAmyloidogenic ProteinsBiomarkers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.